In Brief This Week: Bio-Rad; PacBio; Qiagen; SQI Diagnostics; Integrated DNA Technologies | GenomeWeb

NEW YORK (GenomeWeb News) – In the latter half of 2013, Bio-Rad Laboratories accrued $35 million in costs associated with its initial efforts to resolve investigations into violations of federal anti-bribery laws, the company said in its Form 10-K this week. The company had previously said that in 2010 it disclosed to the US Department of Justice and the US Securities and Exchange Commission that conduct by certain of its overseas operations may have violated the anti-bribery provisions of the US Foreign Corrupt Practices Act.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.